SureTrader
Interactive Brokers Advertisement
Home > Boards > US OTC > Medical - Healthcare >

GT Biopharma Inc. (GTBP)

GTBP RSS Feed
Add GTBP Price Alert      Hide Sticky   Hide Intro
Moderator: CashBowski, BDavid5
Search This Board: 
Last Post: 10/19/2017 3:53:59 AM - Followers: 172 - Board type: Free - Posts Today: 0


 

Oxis International Inc.

Below shows OXS-1550 WORKING - Soon to enter Phase II with FDA!

Overview

Treating Non-Hodgkin's lymphoma

OXS-1550 targets cancer cells expressing the CD19 receptor or CD22 receptor or both receptors. When OXS-1550 binds to cancer cells, the cancer cells internalize OXS-1550 and are killed due to the action of drug's cytotoxic payload. OXS-1550 has demonstrated success in early human clinical trials in patients with relapsed/refractory B-cell lymphoma or leukemia.

Treating triple-negative breast cancer

Our lead drug candidate, OXS-2175, is a small molecule therapeutic candidate targeting the treatment of triple-negative breast cancer. In in vitro and in vivo models of TNBC, OXS-2175 demonstrated the ability to inhibit metastasis.

Treating multiple myeloma

Our lead drug candidate, OXS-4235, also a small molecule therapeutic candidate, targets the treatment of multiple myeloma and associated osteolytic lesions. In in vitro and in vivo models of multiple myeloma and osteoporosis, OXS-4235 demonstrated the ability to kill multiple myeloma cells, and decrease osteolytic lesions in bone.


Management



 

Company Website
http://oxis.com

 


Corporate Overview - Presentation
Fall 2015
Click the link: http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=10968247


 




 





 

 

OXIS Conference Call  March 31, 2015

CEO Interview with The Wolf of Weedstreet

 

SCIENTIFIC ADVISORY BOARD

XIANG-QUN (SEAN) XIE, M.D., Ph.D., EMBA

Sean Xie, MD, PhD, EMBA is a tenured Professor at the Department of Pharmaceutical Sciences/Drug Discovery Institute at University of Pittsburgh and Associate Dean for Research Innovation at the School of Pharmacy. He is Principal Investigator of an integrated research laboratory of CompuGroup, BioGroup and ChemGroup, and Founding Director of Computational Chemical Genomics Screening Center. Dr. Xie is also Director/PI of NIH funded National Center of Excellence for Computational Drug Abuse Research. Dr. Xie holds joint faculty positions at the Departments of Computational System Biology and Structural Biology, and Pittsburgh Cancer Institute MT/DD Program. He serves as an invited guest editor for AAPS Journal, Editorial Board of American Journal of Molecular Biology, and Associate Editor of BMC Pharmacology and Toxicology. In 2013, he was named an honorary professor of Chinese Academy of Medical Sciences & Peking Union Medical College. Dr. Xie is a recipient of the 2014 American Association of Pharmaceutical Scientists (AAPS) Outstanding Research Achievement Award.

JAMES J. MULE, Ph.D.

Dr. James J. Mule, Ph.D. serves as an Executive Vice President and Associate Center Director for Translational Research, the Michael McGillicuddy Endowed Chair for Melanoma Research and Treatment, and the Co-Director of the Donald A. Adam Comprehensive Melanoma Center at the Moffitt Cancer Center. He then moved to Palo Alto, Calif., where he was involved in the birth of two startup companies while an adjunct faculty member in the Department of Surgery, Stanford University. He moved to Ann Arbor, Mich., as the Director of the Tumor Immunology and Immunotherapy Clinical Research Programat the University of Michigan Comprehensive Cancer Center. Dr. Mule is recognized for his translational research studies in cancer immunotherapy. His research group is involved in vaccine strategies and other approaches to stimulate the immune system to recognize and destroy tumors. The work in these areas has helped to develop new treatments for advanced cancer patients. Dr. Mule serves on the Advisory Boards of seven NCI-designated Cancer Centers and was a member of the NCI’s Board of Scientific and Clinical Counselors. He serves as Chair of the Cellular, Tissue and Gene Therapy Advisory Committee of CBER, FDA, is a Special Government Employee of the NCI and the FDA. Dr. Mule is recognized for his research and clinical contributions to cancer immunotherapy, particularly in solid tumors.

STEPHEN M. CHANG, Ph.D.

Dr. Stephen M. Chang is Vice President-Research & Development at New York Stem Cell Foundation, Chief Scientific Officer at Stemgent, Inc., and Independent Director at MultiCell Technologies, Inc. He is on the Board of Directors at MultiCell Technologies, Inc. Dr. Chang was previously employed as Chief Scientific Officer & Vice President by Canji, Inc., Chief Scientific Officer & Vice President by Schering-Plough Research Institute, and President & Chief Executive Officer by MultiCell Immunotherapeutics, Inc. He also served on the board at Histogen, Inc. He received his undergraduate degree from the University of Michigan and a doctorate degree from the University of California, Irvine.

LISA A. HAILE, Ph.D.

Dr. Haile has special technical experience in molecular biology, immunology, plant biotechnology, including transgenic plants, cell biology, diagnostics, therapeutics, theranostics, virology, drug delivery systems, host-vector systems, high throughput screening and bioinformatics. She has particular experience with patentability, non-infringement and validity opinions; licensing strategies; FDA counseling; due diligence work in connection with venture capital, private and public financing; mergers and acquisitions in the life sciences industry; and strategic counseling for comprehensive life sciences patent portfolio management. Dr. Lisa Haile concentrates on patent protection.

 

Information on Multiple Myeloma & Cannabidiol (CBD)

After studying the effects of cannabidiol on multiple myeloma cells, researchers found that; “CBD by itself or in synergy with BORT strongly inhibited growth, arrested cell cycle progression and induced MM cells death by regulating the ERK, AKT and NF-κB pathways with major effects in TRPV2+ cells.”

They conclude that; “These data provide a rationale for using CBD to increase the activity of proteasome inhibitors in MM.”

The study, which validates a recent National Institute of Health study which also found that cannabidiol can inhibit cancer cells, was conducted by researchers at the School of Pharmacy at the University of Camerino in Italy.

 Chart

Stock Information:


 
SureTrader
Interactive Brokers Advertisement
GTBP
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
GTBP News: Current Report Filing (8-k) 10/12/2017 03:01:33 PM
GTBP News: Amended Statement of Ownership (sc 13g/a) 10/10/2017 08:25:05 AM
PostSubject
#9588  Sticky Note The topic of this board is OXIS. The CashBowski 03/31/17 11:03:34 AM
#11315   LOL! Thanks for sharing.... JayP-Diddy 10/18/17 08:57:13 AM
#11312   Thanks, I plan on it. I made so simon wagstaff 10/17/17 04:50:08 PM
#11311   GT Biopharma Announces Stock Sales Agreement with Holders JayP-Diddy 10/17/17 04:49:45 PM
#11310   please do..... JayP-Diddy 10/17/17 02:03:58 PM
#11309   More news!! http://biotechstocks.com/gt-biopharma-inc-gtbp-begins-manufacturing- Oharper 10/17/17 11:42:23 AM
#11308   I think 500,000 OS could be a mistake. MrBond007 10/17/17 09:21:28 AM
#11307   Shoot, if it hits 7 just might short simon wagstaff 10/13/17 09:47:30 PM
#11306   Thanks for posting this info. Very informative. surfgreen 10/13/17 04:09:10 PM
#11305   GTBP = Opportunity due to misinformation ... JoeDaddy 10/13/17 09:45:24 AM
#11304   Ok Shorty McShorter, that's a good one.......... I mrcraigo 10/12/17 04:12:18 PM
#11303   No support until pocket change... sicric 10/12/17 03:32:22 PM
#11302   Here is some new news http://biotechstocks.com/gt-biopharma-inc-gtbp-announces-s Oharper 10/12/17 03:27:37 PM
#11301   If they are going to uplist they will simon wagstaff 10/12/17 11:05:50 AM
#11300   From there website i signed up for news on Bishop123 10/12/17 09:46:13 AM
#11299   If you’re hoping they read out study results, Rando3 10/11/17 08:32:35 AM
#11298   What email? Can you elaborate... CashBowski 10/10/17 06:35:05 PM
#11297   I still think the ownership of OXS-1550 is simon wagstaff 10/10/17 09:38:45 AM
#11296   GTBP Announces Completion of First Four Patients in BDavid5 10/10/17 09:24:57 AM
#11295   New email out any ideas? Bishop123 10/10/17 08:39:24 AM
#11294   worth $1 munimi 10/09/17 03:15:52 PM
#11293   Tell me some more about your conversations with simon wagstaff 10/09/17 02:12:28 PM
#11292   Paid promo. Looks like another r/s to stay simon wagstaff 10/09/17 12:03:09 PM
#11291   New article Oharper 10/09/17 09:52:50 AM
#11290   2 years, continuous spiral downward, 2 r/s. Gibba 10/07/17 01:48:08 PM
#11289   You have spoken directly to researchers involved in simon wagstaff 10/06/17 05:50:57 PM
#11288   Is the R/S player in Nasdaq yet? chromaticity 10/06/17 05:24:47 PM
#11287   I just mean that when you consider the Rando3 10/06/17 10:21:43 AM
#11286   Great news? Please elaborate. simon wagstaff 10/04/17 10:15:38 AM
#11285   Agree lots of great news. Stick won’t move Rando3 10/03/17 02:48:14 PM
#11284   Wonder why this stock is still under $6. RCHAJV 10/03/17 12:20:50 PM
#11283   http://biotechstocks.com/gt-biopharma-gtbp-conference-call-recording-from-10217/ RCHAJV 10/03/17 12:14:57 PM
#11282   Usually someone will write an article on the Gumby525 10/03/17 09:23:48 AM
#11281   Was anyone able to listen to the call? JayP-Diddy 10/03/17 09:15:42 AM
#11280   Yea really I'm wondering what kind of progress Gumby525 10/02/17 08:17:13 PM
#11279   Well what'd they say on the call? oxis007 10/02/17 06:09:06 PM
#11278   Looking forward to the news myself! Oharper 10/02/17 11:49:31 AM
#11277   I'm sure they will have well-informed updates on Suarezzz1111 10/02/17 11:23:08 AM
#11276   I'm actually excited to hear what the new Oharper 10/02/17 11:14:43 AM
#11275   You should just have lowered your order enough Axel 10/02/17 10:42:57 AM
#11274   Will the promos ever stop lol Doesn’t even move anymore Axel 10/02/17 10:41:29 AM
#11273   GTBP up 5% today Oharper 09/29/17 11:41:06 AM
#11272   I agree. I was up thousands and should Gumby525 09/28/17 03:14:59 PM
#11271   Well I have to admit. As a capttom1 09/28/17 01:55:30 PM
#11270   $1 is the next station, Cataldo is known munimi 09/28/17 01:23:31 PM
#11269   I don't want any shareholder to get hurt ammobox 09/28/17 10:50:20 AM
#11268   Paid promotion needs to be more effective. simon wagstaff 09/28/17 10:46:24 AM
#11267   New Tweets from $GTBP ammobox 09/28/17 10:45:43 AM
#11266   Biotech Stocks Pre Market Update – September 28, 2017 ammobox 09/28/17 10:43:03 AM
#11265   I've been shorting since 15, I don't need simon wagstaff 09/27/17 03:28:32 PM
#11264   ready for another R/S? chromaticity 09/27/17 02:38:13 PM
PostSubject